text: Genta Can #39;t Catch a Break Genta (GNTA:Nasdaq - news - research) is never boring! Monday night, the company announced that its phase III Genasense study in chronic lymphocytic leukemia (CLL) met its primary endpoint, which was tumor shrinkage.